Not Yet RecruitingNot Applicable

Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment

France10 participantsStarted 2026-05

Plain-language summary

The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 and older * Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery Exclusion Criteria: * Patients who refuse surgical treatment for arteriovenous malformation * Contraindications to 18F-FDG PET (uncontrolled diabete) * Patients' inability to lie still for 40 minutes * Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders * Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code) * Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code) * Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code) * Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code) * Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code) * Failure to obtain written informed consent

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Standardized Uptake Value (SUV)

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in K1 Transfer Constant

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in Ki Net Influx Rate Constant

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in Cerebral Metabolic Rate of glucose (CMRglu)

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Trial details

NCT IDNCT07569887

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-11

Contact for this trial

Lucas RIBEIRO, Dr

0467337432 l-ribeiro@chu-montpellier.fr

View on ClinicalTrials.gov More Unruptured Brain Arteriovenous Malformation trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in Standardized Uptake Value (SUV)

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in K1 Transfer Constant

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in Ki Net Influx Rate Constant

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation

Change in Cerebral Metabolic Rate of glucose (CMRglu)

Timeframe: Before and at 6 months after surgical treatment of unruptured arteriovenous malformation